References
- Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, et al.. The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospecitve comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49–53.
- Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al.. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079–88.
- Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al.. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–74.
- Ferrajoli A, O’Brien SM, Wierda W, Lerner S, Faderl S, Kantarjian H, et al.. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma. 2005;46:S87.
- Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, et al.. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007;109:2291–8.
- Gerrie AS, Toze CL, Ramadan KM, Li CH, Sutherland J, Yee A, et al.. Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials. Leuk Lymphoma. 2012;53(1):77–82.
- Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118:4313–20.
- Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367–75.
- Shanafelt TD, Tun HW, Hanson CA, Zent CS, Leis JF, Call TG, et al.. Lenalidomide consolidation appears to prolong time to retreatment after first-line chemoimmunotherapy for patients with previously untreated CLL.Blood. 2011; 118:Abstract 3899.
- Shanafelt TD, Lanasa MC, Zent CS, Leis JF, Call TG, LaPlant BR, et al.. Ofatumumab based chemoimmunotherapy (CIT) for patients with previously untreated CLL. Blood. 2011; 118:Abstract 3898.